EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, NUVL: Nuvalent Inc Cl A

30 Oct 25 15:59
LAST:

98.17

CHANGE:
 4.80		OPEN:
102.71		HIGH:
104.90		ASK:
0.00		VOLUME:
873.5K
CHG(%):
4.66		PREV:
102.97		LOW:
96.09		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
30 Oct 25103.81104.9096.0998.171.28M
29 Oct 25100.88103.9299.59102.97552.9K
28 Oct 2597.15101.4695.66101.22594.7K
27 Oct 2594.95101.0094.8797.711.2M
24 Oct 2591.9195.9990.8093.39853.7K
23 Oct 2590.8892.0290.0090.89302.0K
22 Oct 2596.9297.9490.7290.88605.4K
21 Oct 2597.9999.9495.5697.18644.4K
20 Oct 2593.0798.5491.7297.97789.5K
17 Oct 2589.2892.9088.8592.52351.6K

COMPANY PROFILE

Name:Nuvalent Inc Cl A
About:Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:One Broadway, Cambridge, MA, United States, 02142
Website:https://www.nuvalent.com
CUSIP:670703107
CIK:0001861560
ISIN:US6707031075
FIGI:BBG00Z1SLMK5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:98.690.5%
MA10:96.292.0%
MA20:91.497.3%
MA50:84.0816.8%
MA100:81.3520.7%
MA200:78.3125.4%
STO9:52.00
STO14:66.75
RSI14:61.44 
WPR14:-26.22
MTM14:8.42
ROC14:0.09 
ATR:5.25 
Week High:104.906.9%
Week Low:90.009.1%
Month High:104.906.9%
Month Low:81.0225.4%
Year High:104.906.9%
Year Low:55.5476.8%
Volatility:28.76